The Conversation (0)
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to present its Preliminary Final Year Report.
PRELIMINARY FINAL REPORT
For the year ended 31 December 2023, previous corresponding period is 31 December 2022.
CHANGE OF COMPANY NAME
On 31 May 2023, the Company announced that at the Annual General Meeting held on that date a resolution was passed by shareholders to change the Company’s name from Creso Pharma Limited (ASX: CPH) to Melodiol Global Health Limited (ASX: ME1). The change of name took effect on ASX from the commencement of trading on 13 June 2023
RESULTS FOR ANNOUNCEMENT TO THE MARKET
DIVIDENDS
No dividends have been paid or declared by the Group during the year (2022: Nil). No dividend is recommended in respect of the current financial year (2022: Nil).
Click here for the full ASX Release
This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
ME1:AU
